Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 2,552 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 2,552 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total transaction of $233,201.76. Following the completion of the sale, the chief executive officer now directly owns 230,319 shares of the company’s stock, valued at $21,046,550.22. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, April 15th, Steven Leonard Chapman sold 6,816 shares of Natera stock. The stock was sold at an average price of $93.13, for a total transaction of $634,774.08.
• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The stock was sold at an average price of $90.42, for a total transaction of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The stock was sold at an average price of $88.96, for a total transaction of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $824,045.36.
• On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The stock was sold at an average price of $65.09, for a total transaction of $964,178.17.

Natera Stock Performance

NASDAQ NTRA traded up $2.43 during trading hours on Tuesday, hitting $91.04. 1,178,233 shares of the company’s stock traded hands, compared to its average volume of 1,470,075. The business’s fifty day moving average price is $86.40 and its two-hundred day moving average price is $66.49. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $10.99 billion, a P/E ratio of -24.02 and a beta of 1.37. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $98.82.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. The business had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. Equities research analysts predict that Natera, Inc. will post -2.35 EPS for the current year.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently modified their holdings of NTRA. Norges Bank bought a new position in shares of Natera in the fourth quarter worth approximately $83,970,000. American Century Companies Inc. boosted its position in shares of Natera by 115.7% during the third quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company’s stock worth $73,203,000 after acquiring an additional 887,409 shares during the last quarter. Invesco Ltd. boosted its position in shares of Natera by 52.0% during the third quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company’s stock worth $111,930,000 after acquiring an additional 865,404 shares during the last quarter. Perceptive Advisors LLC boosted its position in shares of Natera by 289.7% during the fourth quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock worth $53,258,000 after acquiring an additional 632,047 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Natera by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock worth $687,280,000 after acquiring an additional 588,147 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NTRA. Canaccord Genuity Group increased their price target on shares of Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective for the company in a research note on Friday, April 5th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Tuesday. Raymond James lowered shares of Natera from a “strong-buy” rating to an “outperform” rating and raised their price objective for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. Finally, The Goldman Sachs Group raised their price objective on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, April 15th. One research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.